Vaishali Pharma Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: December 5, 2025, 4:41 am

Competitors of Vaishali Pharma Ltd

All Competitor Stocks of Vaishali Pharma Ltd

Quarterly Result

Last Updated: August 20, 2025, 1:35 am

Below is a detailed analysis of the quarterly data for Vaishali Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 23.75 Cr.. The value appears to be declining and may need further review. It has decreased from 32.25 Cr. (Mar 2025) to 23.75 Cr., marking a decrease of 8.50 Cr..
• For Expenses, as of Jun 2025, the value is 22.38 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 38.29 Cr. (Mar 2025) to 22.38 Cr., marking a decrease of 15.91 Cr..
• For Operating Profit, as of Jun 2025, the value is 1.37 Cr.. The value appears strong and on an upward trend. It has increased from -6.04 Cr. (Mar 2025) to 1.37 Cr., marking an increase of 7.41 Cr..
• For OPM %, as of Jun 2025, the value is 5.77%. The value appears strong and on an upward trend. It has increased from -18.73% (Mar 2025) to 5.77%, marking an increase of 24.50%.
• For Other Income, as of Jun 2025, the value is 0.84 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2025) to 0.84 Cr., marking a decrease of 0.16 Cr..
• For Interest, as of Jun 2025, the value is 0.33 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.44 Cr. (Mar 2025) to 0.33 Cr., marking a decrease of 0.11 Cr..
• For Depreciation, as of Jun 2025, the value is 0.14 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.12 Cr. (Mar 2025) to 0.14 Cr., marking an increase of 0.02 Cr..
• For Profit before tax, as of Jun 2025, the value is 1.74 Cr.. The value appears strong and on an upward trend. It has increased from -5.60 Cr. (Mar 2025) to 1.74 Cr., marking an increase of 7.34 Cr..
• For Tax %, as of Jun 2025, the value is 26.44%. The value appears to be increasing, which may not be favorable. It has increased from -23.39% (Mar 2025) to 26.44%, marking an increase of 49.83%.
• For Net Profit, as of Jun 2025, the value is 1.28 Cr.. The value appears strong and on an upward trend. It has increased from -4.29 Cr. (Mar 2025) to 1.28 Cr., marking an increase of 5.57 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.12. The value appears strong and on an upward trend. It has increased from -0.40 (Mar 2025) to 0.12, marking an increase of 0.52.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 4:11 am

Growth

Last Updated: September 5, 2025, 1:50 pm

Balance Sheet

Last Updated: December 4, 2025, 2:11 am

Below is a detailed analysis of the balance sheet data for Vaishali Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 26.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 26.00 Cr..
• For Reserves, as of Sep 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 39.00 Cr. (Mar 2025) to 41.00 Cr., marking an increase of 2.00 Cr..
• For Borrowings, as of Sep 2025, the value is 16.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 12.00 Cr. (Mar 2025) to 16.00 Cr., marking an increase of 4.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 39.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 33.00 Cr. (Mar 2025) to 39.00 Cr., marking an increase of 6.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 122.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 110.00 Cr. (Mar 2025) to 122.00 Cr., marking an increase of 12.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
• For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
• For Investments, as of Sep 2025, the value is 5.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 5.00 Cr., marking an increase of 5.00 Cr..
• For Other Assets, as of Sep 2025, the value is 114.00 Cr.. The value appears strong and on an upward trend. It has increased from 107.00 Cr. (Mar 2025) to 114.00 Cr., marking an increase of 7.00 Cr..
• For Total Assets, as of Sep 2025, the value is 122.00 Cr.. The value appears strong and on an upward trend. It has increased from 110.00 Cr. (Mar 2025) to 122.00 Cr., marking an increase of 12.00 Cr..

Notably, the Reserves (41.00 Cr.) exceed the Borrowings (16.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Vaishali Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 10.00 (Mar 24) to 2.00, marking a decrease of 8.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has decreased from 0.68 (Mar 24) to 0.06, marking a decrease of 0.62.
• For Diluted EPS (Rs.), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has decreased from 0.64 (Mar 24) to 0.06, marking a decrease of 0.58.
• For Cash EPS (Rs.), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 3. It has decreased from 1.14 (Mar 24) to 0.09, marking a decrease of 1.05.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 4.98. It has decreased from 33.41 (Mar 24) to 4.98, marking a decrease of 28.43.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 4.98. It has decreased from 33.41 (Mar 24) to 4.98, marking a decrease of 28.43.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 7.59. It has decreased from 80.49 (Mar 24) to 7.59, marking a decrease of 72.90.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 0.25. This value is below the healthy minimum of 2. It has decreased from 2.96 (Mar 24) to 0.25, marking a decrease of 2.71.
• For PBIT / Share (Rs.), as of Mar 25, the value is 0.21. This value is within the healthy range. It has decreased from 2.48 (Mar 24) to 0.21, marking a decrease of 2.27.
• For PBT / Share (Rs.), as of Mar 25, the value is 0.09. This value is within the healthy range. It has decreased from 0.86 (Mar 24) to 0.09, marking a decrease of 0.77.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 2. It has decreased from 0.67 (Mar 24) to 0.06, marking a decrease of 0.61.
• For PBDIT Margin (%), as of Mar 25, the value is 3.32. This value is below the healthy minimum of 10. It has decreased from 3.67 (Mar 24) to 3.32, marking a decrease of 0.35.
• For PBIT Margin (%), as of Mar 25, the value is 2.83. This value is below the healthy minimum of 10. It has decreased from 3.08 (Mar 24) to 2.83, marking a decrease of 0.25.
• For PBT Margin (%), as of Mar 25, the value is 1.23. This value is below the healthy minimum of 10. It has increased from 1.07 (Mar 24) to 1.23, marking an increase of 0.16.
• For Net Profit Margin (%), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 5. It has decreased from 0.83 (Mar 24) to 0.82, marking a decrease of 0.01.
• For Return on Networth / Equity (%), as of Mar 25, the value is 1.25. This value is below the healthy minimum of 15. It has decreased from 2.00 (Mar 24) to 1.25, marking a decrease of 0.75.
• For Return on Capital Employeed (%), as of Mar 25, the value is 4.02. This value is below the healthy minimum of 10. It has decreased from 5.68 (Mar 24) to 4.02, marking a decrease of 1.66.
• For Return On Assets (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 5. It has decreased from 0.89 (Mar 24) to 0.74, marking a decrease of 0.15.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.10 (Mar 24) to 0.06, marking a decrease of 0.04.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.17. This value is within the healthy range. It has decreased from 0.35 (Mar 24) to 0.17, marking a decrease of 0.18.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.04. It has decreased from 1.09 (Mar 24) to 1.04, marking a decrease of 0.05.
• For Current Ratio (X), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from 2.25 (Mar 24) to 2.61, marking an increase of 0.36.
• For Quick Ratio (X), as of Mar 25, the value is 2.49. This value exceeds the healthy maximum of 2. It has increased from 2.24 (Mar 24) to 2.49, marking an increase of 0.25.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 38.16. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 38.16, marking an increase of 38.16.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 2.08. This value is below the healthy minimum of 3. It has increased from 1.83 (Mar 24) to 2.08, marking an increase of 0.25.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.52. This value is below the healthy minimum of 3. It has increased from 1.41 (Mar 24) to 1.52, marking an increase of 0.11.
• For Enterprise Value (Cr.), as of Mar 25, the value is 173.94. It has increased from 161.15 (Mar 24) to 173.94, marking an increase of 12.79.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.76. This value is within the healthy range. It has decreased from 1.87 (Mar 24) to 1.76, marking a decrease of 0.11.
• For EV / EBITDA (X), as of Mar 25, the value is 52.78. This value exceeds the healthy maximum of 15. It has increased from 50.82 (Mar 24) to 52.78, marking an increase of 1.96.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.66. This value is within the healthy range. It has decreased from 1.74 (Mar 24) to 1.66, marking a decrease of 0.08.
• For Price / BV (X), as of Mar 25, the value is 2.53. This value is within the healthy range. It has decreased from 4.19 (Mar 24) to 2.53, marking a decrease of 1.66.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.66. This value is within the healthy range. It has decreased from 1.74 (Mar 24) to 1.66, marking a decrease of 0.08.
• For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness